Polycythemia vera (PV) is a relatively indolent myeloid neoplasm with median survival that
exceeds 35 years in young patients, but its natural history might be interrupted by …

Polycythaemia vera is associated with a reduced quality of life, a high rate of vascular
events, and an intrinsic risk of disease evolution. The results of several randomised trials for …

Abstract Disease Overview Polycythemia vera (PV) is a JAK2‐mutated myeloproliferative
neoplasm characterized by clonal erythrocytosis; other features include leukocytosis …

The goal of therapy for patients with essential thrombocythemia (ET) and polycythemia vera
(PV) is to reduce thrombotic events by normalizing blood counts. Hydroxyurea (HU) and …

Patients with polycythemia vera (PV), an incurable Philadelphianegative myeloproliferative
neoplasm, have shortened survival due to thrombohemorrhagic complications and evolution …

Interferon alfa not only restores normal blood cell counts in patients with polycythemia vera
(PV) but can diminish the mutant JAK2V617F allele burden [1, 2, 3]. After discontinuing long …

Polycythemia vera (PV) is a hematopoietic stem cell neoplasm defined by activating somatic
mutations in the JAK2 gene and characterized clinically by overproduction of red blood cells …

Ropeginterferon alfa-2b is a novel, long-acting mono-pegylated proline-IFN-alpha-2b
approved for treatment of polycythemia vera in adults, regardless of thrombotic risk level or …

Polycythemia vera (PV) belongs to the BCR-ABL1–negative myeloproliferative neoplasms
and is characterized by activating mutations in JAK2 and clinically presents with …

Abstract Purpose of Review Estimating and modifying thrombotic risk is currently the
mainstay of care for patients with polycythemia vera (PV) and essential thrombocythemia …